Adults with type 2 diabetes who took a GLP-1 receptor agonist while maintaining six to eight healthy lifestyle habits ...

A new drug offers hope for people with hypertrophic cardiomyopathy, the world's most common inherited heart disease. The ...

Researchers at University College London have identified a specific mechanism by which GLP-1 receptor agonists, the drug ...

If you’re looking for ways to mitigate your risk of developing cardiovascular disease or experiencing a cardiac event, such as a heart attack or stroke, glucagon-like peptide-1 (GLP-1) receptor ...

A meta-analysis of 10 randomized controlled trials involving more than 23,000 participants, presented at the International ...

Polypharmacy in patients with cardiovascular disease occurs frequently across the age spectrum and can lead to inappropriate ...

GLP-1 receptor agonists such as semaglutide are changing the way type 2 diabetes and obesity are treated. But these drugs have also shown a surprising ability to improve cardiovascular health — and ...

Liz covers cardiovascular and metabolic disease, asking why we’re not doing better or even losing ground against the world’s leading killer. Send tips on Signal at LizC.22. Leading medical ...

People who use drugs with anticholinergic effects, including certain antidepressants, drugs for urinary incontinence and common antihistamines, are at higher risk of developing cardiovascular disease.

Medical innovation has really give people a shot at better heart health. About 805,000 people in the US have heart attacks every year, with one occurring every 40 seconds — and an alarming increase in ...

Managing risk factors is the key to further progress in reducing deaths from coronary artery disease, a new study finds.

An international study found that finerenone slows kidney function decline and reduces the risk of serious kidney and ...